The cause of disease and its mechanisms for Alzheimer's disease have not been identified, but Senile plaque and Neurofibrillary tangle have been observed in the patient's brain, and the discovery of the neuro-cellular apoptosis, synaptic loss, Tau proteins degeneration, and the formation mechanism of nerve fiber mass by hyperphosphorylation caused by toxic proteins such as amyloid-beta and APP-C proteins, many studies are underway, including the establishment of ideal disease models, new prevention and treatment methods.
In fact, over the last 30 years, a variety of studies have been conducted on the cause of disease and treatment mechanisms of Alzheimer's disease, and many clinical trials have been conducted. In particular, in degenerative brain diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, the therapeutic effects of nerve cell regeneration techniques by stem cells have been identified in animal models, and Neurogenic inflammation are also important in Alzheimer's disease. Therefore, research into the prevention and treatment of brain diseases through the control of Neurogenic inflammation has recently been recognized as an important area.
However, there are still no effective treatment method or medicine available to prevent or treat Alzheimer's disease, other than medication that relieves the symptoms of mental and behavioral disorders.
"Cell therapy" is therapy in which cellular material is injected, grafted or implanted into a patient;this generally means intact, living cells. For example, T cells capable of fighting cancer cells via cell-mediated immunity may be injected in the course of immunotherapy. Cell therapy originated in the nineteenth century when scientists experimented by injecting animal material in an attempt to prevent and treat illness. Although such attempts produced no positive benefit, further research found in the mid twentieth century that human cells could be used to help prevent the human body rejecting transplanted organs, leading in time to successful bone marrow transplantation. Today two distinct categories of cell therapy are recognized. The first category is cell therapy in mainstream medicine. This is the subject of intense research and the basis of potential therapeutic benefit. Such research can be controversial when it involves human embryonic material. The second category is in alternative medicine, and perpetuates the practice of injecting animal materials in an attempt to cure disease. This practice, according to the American Cancer Society, is not backed by any medical evidence of effectiveness, and can have deadly consequences.
“Regulatory T cells (Treg)” are a type of T cell that has characteristics that control the inflammatory response of abnormally active immune cells. Excessive immune responses result in autoimmune diseases, including rheumatoid arthritis, lupus and psoriasis, and hypersensitive lesions such as asthma and atopic dermatitis. Studies have shown that these diseases are significantly alleviated by the injection of regulated T cells. Therefore, domestic and foreign pharmaceutical companies are competing to develop treatments using regulatory T cells. Recently, a new paradigm has been formed in the development of degenerative brain disease treatments, with the publication of a thesis suggesting that regulatory T cells are involved in inflammatory brain diseases such as dementia, Parkinson’s disease and amyotrophic lateral sclerosis as well as general immune disorders.
Because control T cells are naturally produced cells in our bodies, they are safe, and they are not differentiating cells, such as stem cells, so there is an advantage that they can be free from cancer caused by cell growth being unregulated. also, our researchers expect that highly effective treatments will be made with the technology to isolate and culture target-regulatory T cells that are specific to Alzheimer's disease, and to amplify them in large quantities.
Our specific regulatory T-cell separation and large quantities production technologies have been named TTE01 (Therapeutic Treg Enhancer) systems. This technology is used to culture specific regulatory T cells to certain diseases, and it is possible to develop cellular therapy for other degenerative brain diseases such as Parkinson's disease, Huntington's disease and rheumatoid arthritis, lupus, and organ transplant rejection.